Autocrine human growth hormone enhancement of human mammary carcinoma cell spreading is Jak2 dependent.
We investigated the role of autocrine production of human (h) GH in the attachment and spreading of mammary carcinoma cells in vitro. We used a previously described model system for the study of the autocrine/paracrine role of GH in which the hGH gene (MCF-hGH) or a translation-deficient hGH gene (MCF-MUT) was stably transfected into MCF-7 cells. No differences in attachment to a collagen matrix between MCF-hGH and MCF-MUT cells were observed in either serum-free medium (SFM) or medium containing exogenous hGH, 5% serum, or 10% serum. In contrast, MCF-hGH cells spread more rapidly on a collagen matrix than did MCF-MUT cells. Exogenous hGH and 10% serum interacted with autocrine production of hGH in an additive manner to increase cell spreading. MCF-hGH cells formed filipodia and stress fibers earlier than MCF-MUT cells during the process of cell spreading and possessed marked differences in morphology after spreading. MCF-MUT cells displayed uniform and symmetrical formation of stress fibers, whereas MCF-hGH cells displayed irregular and elongated stress fiber formation. The level of cytoplasmic phosphotyrosine was increased in MCF-hGH compared with MCF-MUT cells during spreading and displayed colocalization with Janus kinase 2 (JAK2). Basal JAK2 tyrosine phosphorylation was increased, and it increased further on spreading in MCF-hGH cells compared with MCF-MUT cells. Transient transfection of JAK2 complementary DNA resulted in interaction with autocrine hGH to increase the rate of cell spreading in MCF-hGH cells compared with MCF-MUT cells. Treatment with a selective JAK2 tyrosine kinase inhibitor (AG 490) reduced the rate of MCF-hGH cell spreading to the rate of MCF-MUT cell spreading. Thus, we conclude that autocrine production of hGH enhances the rate of mammary carcinoma cell spreading in a JAK2-dependent manner.
Kaulsay
K K
KK
Department of Medicine, National University of Singapore, Republic of Singapore.
Mertani
H C
HC
Lee
K O
KO
Lobie
P E
PE
D000199:Actins / Q000502:physiology; D019898:Autocrine Communication / Q000502:physiology*; D001943:Breast Neoplasms / Q000473:pathology* / Q000503:physiopathology; D002277:Carcinoma / Q000473:pathology* / Q000503:physiopathology; D002448:Cell Adhesion; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D013006:Growth Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D019382:Human Growth Hormone / Q000502:physiology*; D006801:Humans; D053614:Janus Kinase 2; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D011518:Proto-Oncogene Proteins; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured / Q000502:physiology; D014443:Tyrosine / Q000378:metabolism; D020032:Tyrphostins / Q000494:pharmacology
D000199:Actins; D004791:Enzyme Inhibitors; C093172:G120R protein, human; D006727:Hormone Antagonists; D011518:Proto-Oncogene Proteins; D011986:Receptors, Somatotropin; D011994:Recombinant Proteins; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; D019382:Human Growth Hormone; D019000:Phosphotyrosine; D014443:Tyrosine; D013006:Growth Hormone; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2